Tang and colleagues proposed the use of an antibody-guided LIGHT fusion protein to enhance the efficacy of anti-PD-1 therapy.89 By specifically targeting LIGHT to tumour tissues to stimulate lymphotoxin β receptor (LTβR), the expression of CCL3, CCL4, CCL5, CXCL9 and CXCL10 was increased in tumour cells, resulting in enhanced T-cell infiltration and responsiveness to PDL-1 checkpoint blockade treatment. This evidence concerns the gene CXCL10 and neoplasm.